Immunic, Inc. (IMUX), a late-stage biotechnology company, on Wednesday said it has appointed Erik Lundgren as its new chief executive officer, effective May 22, 2026, with employment set to begin on June 1.
Lundgren succeeds Daniel Vitt, who will continue to oversee scientific strategy and portfolio advancement while remaining a member of Immunic's board of directors.
Lundgren has nearly 20 years of experience in the biopharmaceutical industry, including commercial strategy, global portfolio leadership and product launches, with a strong background in multiple sclerosis. He previously served as senior vice president of the Commercial Portfolio Organization at Genentech, part of the Roche Group
"As we look to our next phase of growth, including the pivotal phase 3 RMS data readout expected by year-end, preparations for NDA filing in this indication and potential commercialization thereafter, Erik's experience will be invaluable," said Michael W. Bonney, Chair of Immunic's Board of Directors.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.